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Abstract 
In order to investigate the role of type II phospholipase A1 (PLA,) in the inflammatory process, the effect of a monoclonal antibody specific to 
type II PLA, on carrageenan-induced pleurisy was studied in rats. Intravenous injection of the antibody (MB5.2), which inhibits the catalytic activity 
of type II PLA,, significantly reduced both the pleural exudate volume and the intrapleural leukocyte count, while a control antibody did not have 
any appreciable ffect. MB5.2 caused no change in the level of type II PLA, in the pleural fluid. These results suggest hat type II PLA, generated 
at inflamed sites, at least in part, have a crucial role in the pathogenesis of acute Inflammation. 
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1. Introduction 2. Materials and methods 
PLA, is considered to play a central role in various 
inflammatory reactions, since it catalyzes the liberation 
of arachidonic acid and lysophospholipids from mem- 
brane phospholipids, and these products then are con- 
verted to proinflammatory mediators such as prosta- 
glandins, leukotrienes, and platelet-activating factor. 
2 1 Preparation of monoclonal antibodies 
Hybridomas producing the anti-type II PLA, antibody (MB5.2) [18] 
or a control antibody were injected into pristane-treated BALBlc mice 
in order to obtain monoclonal antibodies from ascites. The ascitic fluid 
harvested from these mice was purified by 50% ammonium sulfate 
precipitation followed by affinity chromatography on a protein A- 
Sepharose column (Pharmacia) [19], and the purified antibodies were 
dialyzed against 10 mM phosphate-buffered saline (pH 7.4). 
The molecular nature of mammalian PLA, has re- 
cently been clarified. There is a 1CkDa secretory PLA, 
with two isozymes (type I and II) having different pri- 
mary structures [11, and there is also an 85kDa cytosolic 
form of PLA, [2,3]. Type II PLA, is often found in 
extracellular fluid at sites of inflammation [4-81 and the 
administration of type II PLA, results in the exacerba- 
tion of inflammation in some animal models [9-lo]. In 
addition, inflammatory cytokines up-regulate type II 
PLA, expression by certain types of cells [l l-l 51, while 
its expression is suppressed by anti-inflammatory gluco- 
corticoids [ 16,171. These observations uggest hat type 
II PLA, plays a critical role in the process of inflamma- 
tion. However, direct evidence supporting its involve- 
ment in inflammatory reactions has been rather limited. 
2.2. Carrageenan-induced pleurisy 
Male Donryu rats (Charles River, Japan Inc.) weighing 160-180 g 
were used. Solution (0.3 ml) of 0.5% carrageenan (Zusi Kagaku) was 
InJected into the pleural space under ether anesthesia. After 6 h, the 
volume of exudate and the number of leukocytes in the pleural cavity 
were determined. Monoclonal antibodies were injected intravenously 
at various doses 30 min prior to the injection of carrageenan. 
2 3. Quant$cation of Type II PLA, 
The type II PLA, content in pleural fluid was determined by a 
sandwich ELISA [20] using a polyclonal anti-type II PLA, antibody 
(R377) as the solid phase and a soluble biotinylated monoclonal anti- 
type II PLA, antibody (MD7.1). Immunoaffinity-purified type II PLAz 
from rat platelets was diluted to various concentrations for use as a 
standard for quantification. 
3. Results 
In the present study, we investigated the contribution 
of type II PLA, to acute inflammation by using an anti- 
type II PLA, antibody [18] and a rat model of car- 
rageenan-induced pleurisy. 
The monoclonal antibody MB5.2 is known to sup- 
press the catalytic activity of type II PLA, [18]. When it 
was administered to rats with carrageenan-induced pleu- 
risy, there was a dose-dependent reduction in both the 
volume of pleural exudate and the number of intrapleu- 
ral leukocytes (Fig. 1). The pleural exudate volume and 
leukocyte count were significantly decreased by 28% and *Corresponding author. Fax: (81) (3) 3818 3173. 
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Fig. 1. Effect of the antibody MB52 on carrageenan-induced pleurisy 
in rats. The procedures were described in Section 2. Closed bars repre- 
sent the pleural exudate volume and open bars represent he number 
of leukocytes. Values are the mean f S.E.M. (n = 8-10). *P < 0.05 and 
**P < 0.01 vs. the control group. 
29%, respectively, when 2 mg of MB5.2 was intrave- 
nously injected. More increased amounts of MB5.2 did 
not have any further effect (data not shown). The control 
IgG antibody did not appreciably alter the development 
of pleurisy. 
The type II PLA, content in pleural fluid was deter- 
mined using a sandwich ELISA (Fig. 2). The average 
pleural fluid level of type II PLA, in rats injected with 
carrageenan was about three-fold greater than in rats 
injected with saline (12 ng vs. 4 ng, respectively). No 
















Fig. 2. Quantification of the type II PLA2 content of rat pleural fluid 
by sandwich ELISA. The positive control was injected with 0.3 ml of 
0.5% carrageenan and the negative control was injected with 0.3 ml of 
saline. Values are the mean f S.E.M. (n = g-10). 
among rats administered either MB5.2, the control IgG 
antibody or vehicle only. 
We have previously reported that type II PLA, had 
various pharmacological effects on several kinds of cells 
in vitro, it promotes eicosanoid generation by some cells 
[15,21] and also triggers histamine release from mast cells 
[22,23]. Thus, to investigate the mechanism of the inflam- 
matory effect of type II PLA,, we examined the influence 
of indomethacin (a cyclooxygenase inhibitor) and 
mepyramine (an anti-histamine) on the development of 
pleurisy (Fig. 3). Indomethacin markedly suppressed the 
development of pleurisy, whereas mepyramine showed 
no appreciable effect. Thus, type II PLA, might partici- 
pate in the inflammatory process of carrageenan-induced 
pleurisy by potentiating eicosanoid synthesis rather than 
by triggering mast cell degranulation. 
4. Discussion 
Type II PLA2 has been detected in a wide variety of 
types of inflammation [4-Q, and its importance in the 
inflammatory process has been suggested by many inves- 
tigators including ourselves, although there has been lit- 
tle convincing evidence available. In this study, we 
showed that an anti-type II PLA, monoclonal antibody 
(MB5.2) which neutralizes type II PLA, activity [19], 
could significantly reduce both the volume of exudate 
and the number of leukocytes in rats with carrageenan- 
induced pleurisy. To our knowledge, this is the first di- 
rect evidence of the involvement of the catalytic activity 
control 10 mglkg control 100 mglkg 
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Fig. 3. Effect of indomethacin and mepyramine on carrageenan- 
induced pleurisy in rats. Indomethacin (10 mg/kg) or mepyramine 
(100 mg/kg) suspended in 0.5% methylcellulose solution was adminis- 
tered orally 1 h pnor to the injection of carrageenan as described in 
Section 2. Closed bars represent the pleura1 exudate volume and 
open bars represent the number of leukocytes. Values are the 
mean f S.E.M. (n = S-10). **P < 0.01 vs. the control group. 
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of type II PLA, in the inflammatory process. Type II 
PLA, may contribute to eicosanoid generation at sites of 
inflammation by the hydrolysis of phospholipids in the 
plasma membranes of target cells and the liberation of 
arachidonic acid. This hypothesis is consistent with our 
finding that indomethacin, cyclooxygenase inhibitor, 
markedly suppressed carrageenan-induced pleurisy. 
Since the inhibitory effect of indomethacin was greater 
than that of the antibody MB5.2, the involvement of 
some other form of PLA,, such as cytosolic PLA,, could 
also be considered. 
We recently demonstrated that type II PLA, triggers 
mast cell degranulation [22,23]. Since the anti-histamine 
drug, mepyramine, did not have any suppressive ffect 
on pleurisy in this rat model, mast cell degranulation 
induced by type II PLA, might not be so important in 
this type of inflammation. 
Several investigators have suggested that the presence 
of type II PLA, at sites of inflammation was the result 
of transduction of the protein from the plasma [24,25]. 
However, our present finding that the content of type II 
PLA, in pleural fluid was not affected by injection of the 
antibody MB5.2 despite an appreciable decrease in the 
pleural exudate volume and leukocyte count suggests 
that the source of type II PLA, is neither the plasma nor 
the leukocytes exudating into inflamed sites. Some type 
of cell already present in the pleural cavity might be the 
major source of type II PLA, in this pleurisy model. 
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